US 12,012,443 B2
Immunomodulatory fusion proteins and uses thereof
Shannon K. Oda, Lake Forest Park, WA (US); Philip D. Greenberg, Mercer Island, WA (US); and Thomas M. Schmitt, Seattle, WA (US)
Assigned to Fred Hutchinson Cancer Center, Seattle, WA (US)
Filed by Fred Hutchinson Cancer Center, Seattle, WA (US)
Filed on Feb. 3, 2021, as Appl. No. 17/166,903.
Application 17/166,903 is a continuation of application No. 15/555,951, abandoned, previously published as PCT/US2016/021064, filed on Mar. 4, 2016.
Claims priority of provisional application 62/128,979, filed on Mar. 5, 2015.
Prior Publication US 2021/0403532 A1, Dec. 30, 2021
Int. Cl. C07K 14/705 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); A61K 38/00 (2006.01); A61K 48/00 (2006.01)
CPC C07K 14/70596 (2013.01) [A61K 35/17 (2013.01); C07K 14/70503 (2013.01); C07K 14/70507 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C12N 5/0636 (2013.01); C12N 5/0637 (2013.01); C12N 5/0638 (2013.01); A61K 38/00 (2013.01); A61K 48/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/74 (2013.01); C12N 2510/00 (2013.01)] 16 Claims
 
1. A fusion protein comprising the amino acid sequence encoded by a nucleic acid molecule as set forth in any one of SEQ ID NOs.:19, 20, 22, and 23.